- Home
- KURA vs MNKD Comparison
KURA vs MNKD Comparison
Compare KURA & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | MNKD |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | 260 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 877.0M |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | KURA | MNKD |
|---|---|---|
| Price | $9.23 | $3.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $25.56 | $8.69 |
| AVG Volume (30 Days) | 1.2M | ★ 5.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,482,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $28.28 | $35.81 |
| Revenue Next Year | $106.37 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | 22.23 |
| 52 Week Low | $5.45 | $2.23 |
| 52 Week High | $12.49 | $6.51 |
Technical Indicators
Market Signals| Indicator | KURA | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 51.59 |
| Support Level | $8.95 | $2.56 |
| Resistance Level | $9.82 | $6.08 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 50.34 | 25.91 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.